Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis

Gut

Volumn 55, Issue 1, 2006, Pages 26-33

  Yeo, M ^a,b   Kim, D K ^b   Han, S U ^b   Lee, J E ^c   Kim, Y B ^b   Cho, Y K ^b   Kim, J H ^b   Cho, S W ^b   Hahm, K B ^b  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c DNA Link Inc   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; PROTON PUMP INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CARCINOGENESIS; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANTI-ULCER AGENTS; ANTIGENS, CD34; BLOTTING, WESTERN; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENDOTHELIUM, VASCULAR; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; PROTON PUMPS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 29244439368     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.067454     Document Type: Article

References (38)

1. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
2. Stolte M, Bayerdorffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut 2002;50:19-24.
3. Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med 1999;106:222-6.
4. Touati E, Michel V, Thiberge JM, et al. Chronic Helicobacter pylori infections induce gastric mutations in mice. Gastroenterology 2003;124:1408-19.
5. Bagchi D, Bhattacharya G, Stohs SJ. Production of reactive oxygen species by gastric cells in association with Helicobacter pylori. Free Radic Res 1996;24:439-50.
6. Maeda S, Yoshida H, Mitsuno Y, et al. Analysis of apoptotic and antiapoptotic signalling pathways induced by Helicobacter pylori. Gut 2002;50:771-8.
7. Gupta RA, Polk DB, Krishna U, et al. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 2001;276:31059-66.
8. Betten A, Bylund J, Cristophe T, et al. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. J Clin Invest, 2001;108:1221-8.
9. Allen IA. Modulating phagocyte activation: the pros and cons of Helicobacter pylori virulence factors. J Exp Med 2000;191:1451-4.
10. Crawford HC, Krishna US, Israel DA, et al. Helicobacter pylori strain-selective induction of matrix metalloproteinase-7 in vitro and within gastric mucosa. Gastroenterology 2003;125:1125-36.
11. Kitadai Y, Sasaki A, Ito M, et al. Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. Biochem Biophys Res Commun 2003;311:809-14.
12. Cox JM, Clayton CL, Tomita T, et al. cDNA array analysis of cag pathogenicity island-associated Helicobacter pylori epithelial cell response genes. Infect Immun 2001;69:6970-80.
13. Strowski MZ, Cramer T, Schafer G, et al. Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J 2004;18:218-20.
14. Innocenti M, Thoreson AC, Ferrero RL, et al. Helicobacter pylori-induced activation of human endothelial cells. Infect Immun 2002;70:4581-90.
15. Franceschi F, Genta RM, Gasbarrini A, et al. Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma. Dig Liver Dis 2002;34:621-5.
16. +-ATPase. Ann Rev Pharmacol Toxicol 1995;35:277-305.
17. Scott DR, Helander HF, Hersey SJ, et al. The site of acid secretion in the mammalian parietal cell. Biochim Biophys Acta Bio-Membr 1993;1146:73-80.
18. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000;22:266-80.
19. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22-37.
20. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460-82.
21. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6.
22. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998;3:21-7.
23. Hirai M, Azuma T, Ito S, et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 1995;30:461-4.
24. Tsuchiya M, Imamura L, Park JB, et al. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995;18:1053-6.
25. McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology 1994;107:1573-8.
26. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 1993;88:1801-2.
27. Yeo M, Kim DK, Kim YB, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 2004;10:8687-96.
28. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis, the updated Sydney system. Am J Surg Pathol 1996;20:1161-81.
29. Jaffe EA, Nachman RL, Becker CG. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria, J Clin Investt 1973;52, 2745-56.
30. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
31. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004;5:13-17.
32. Baatar D, Jones MK, Tsugawa K, et al. Esophageal ulceration triggers expression of hypoxia-inducible factor-1 alpha and activates vascular endothelial growth factor gene: implications for angiogenesis and ulcer healing. Am J Pathol 2002;161:1449-57.
33. Jones MK, Kawanaka H, Baatar D, et al. Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. Gastroenterology 2001;121:1040-7.
34. Takahashi Y, Cleary KR, Mai M, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996;2:1679-84.
35. Maeda K, Kang SM, Onoda N, et al. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer 1999;86:566-71.
36. Kanai T, Konno H, Tanaka T, et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998;77:933-6.
37. Caputo R, Tuccillo C, Manzo BA, et al. Helicobacter pylori VacA toxin upregulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. Clin Cancer Res 2003;9:2015-21.
38. Park JH, Kim TY, Jong HS, et al. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1 alpha in gastric cancer cells. Clin Cancer Res 2003;9:433-40.